Medscape is available in 5 Language Editions – Choose your Edition here.


Bursitis Treatment & Management

  • Author: Kristine M Lohr, MD, MS; Chief Editor: Harris Gellman, MD  more...
Updated: Oct 13, 2015

Approach Considerations

Most patients with bursitis are treated conservatively to reduce inflammation. Conservative treatment includes rest, cold and heat treatments, elevation, administration of nonsteroidal anti-inflammatory drugs (NSAIDs), bursal aspiration, and intrabursal steroid injections (with or without local anesthetic agents).[16]

Patients with suspected septic bursitis should be treated with antibiotics while awaiting culture results. Superficial septic bursitis can be treated with oral outpatient therapy. Those with systemic symptoms or who are immunocompromised may require admission for intravenous (IV) antibiotic therapy.

Surgical excision of bursae may be required for chronic or frequently recurrent bursitis. Surgery is reserved as a last resort for patients in whom conservative treatment fails. The operation varies according to site.

Most patients respond well to conservative management. Patients who do not respond to nonoperative treatment or who have signs of tendinous or ligamentous injury require further evaluation. Consultation with a general or orthopedic surgeon or a rheumatologist may be helpful.

With regard to resumption of activities, patients should let pain be their guide.


Conservative Treatment

Conservative treatment involves control of pain and inflammation, which may be guided by the PRICEMM acronym, as follows:

  • P rotect - Use padding, braces, or changes in technique
  • R est - Avoid activities that exacerbate pain
  • I ce - Cryotherapy can relieve pain and decrease inflammation
  • C ompression - Elastic dressings can ease pain, as in olecranon bursitis
  • E levation - Raise the affected limb above the level of the heart
  • M odalities – Employ electrical stimulation, ultrasonography, or phonophoresis
  • M edications – Administer nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or corticosteroid injections

Physical measures

The affected area should be placed at rest. Because of the risk of adhesive capsulitis, shoulders should not be immobilized for more than a few days. After immobilization, patients should begin graduated range-of-motion exercises. Patients who have bursitis secondary to overuse should be educated about the importance of regular periods of rest and possible alternative activities to prevent recurrence.

Applying cold treatments for 20 minutes every several hours may be of value in the first 24-48 hours. Such treatments may be followed by heat treatments. Elevation is useful, particularly in lower-limb bursitis. Consider site-specific therapy (eg, cushions for ischial bursitis, well-fitting padded shoes for calcaneal bursitis).

NSAIDs and corticosteroids

NSAIDs are used to reduce inflammation and relieve pain. In a multicenter, double-blind, parallel study involving 372 patients with acute (≤72 hours) traumatic bursitis or tendinitis of the shoulder, 90% of patients treated with diclofenac 50 mg two or three times daily improved over 14 days, with 40-50% demonstrating at least moderate improvement.[26]

Corticosteroid injections can be helpful if the patient does not respond to other treatment within 7-14 days. Various steroids (eg, hydrocortisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, and dexamethasone) have been used in this setting, but no single agent has been found to be demonstrably superior. Steroids can be mixed in the same syringe with lidocaine or bupivacaine.

Corticosteroid injections can be performed either in the emergency department (ED) or in an outpatient setting.[27, 28] A 1.5- to 4-inch 20-gauge spinal needle may be used as a probe to determine the points of maximal tenderness in the affected bursa. Typically, a mix of corticosteroid and local anesthetic is injected into each tender site. An injection of 20 mg or less of corticosteroid should be used per lesion, and no more than a total of 40 mg of corticosteroid should be used.[10, 14, 29]

The potential complications of intrabursal injections include the following:

  • Infection
  • Bleeding
  • Allergy to injected agents
  • Local subcutaneous atrophy (Methylprednisolone is associated with the least frequent development of local subcutaneous atrophy.)
  • Postinjection flare or pain – Postinjection flares usually start within hours and may last up to 72 hours; postinjection pain may last several hours
  • Tendon rupture – Major tendons should not be injected

Intrabursal steroid injections (with or without local anesthetics) should not be performed if infection is suspected. In overuse injuries, injections should not replace cessation or modification of the offending activity.

In a randomized study of 42 patients with olecranon bursitis who were assigned after bursal aspiration to 1 of 4 treatment groups (intrabursal methylprednisolone 20 mg plus naproxen 1 g/day for 10 days, intrabursal methylprednisolone without naproxen, naproxen only, or placebo), steroid injection was more successful in decreasing edema and preventing recurrence than naproxen or placebo was.[30]

In a systematic review of 29 studies involving a total of 1278 patients with olecranon bursitis, Sayegh and Strauch found that treatment of aseptic bursitis with corticosteroids was associated with significantly increased rates of overall complications and skin atrophy. Compared with patients with septic bursitis, those with aseptic bursitis had a significantly higher overall complication rate. Compared with nonsurgical management, surgical management was significantly less likely to clinically resolve septic or aseptic bursitis, and it was associated with significantly higher rates of overall complications, persistent drainage, and bursal infection.[31]

A study comparing the short- and long-term effectiveness of betamethasone injections (6, 12, or 24 mg with 4 mL of 1% lidocaine) for trochanteric bursitis reported that improvement of pain was achieved at 1, 6, and 26 weeks in 77%, 69%, and 61% of patients, respectively.[32] Higher doses of steroids were significantly more effective.

A small-sample-size study found that injection under ultrasonographic guidance may be more efficacious than blind injection based on anatomy.[33]

In a study of 25 cases of postarthroplasty trochanteric bursitis requiring corticosteroid injection, Farmer et al found that corticosteroid injections were effective therapy and that nonoperative management may be more likely to fail in young patients and patients with leg-length discrepancies.[34] Of the 25 hips, 11 required multiple corticosteroid injections, and symptoms resolved in 20 cases.

An 8-week placebo-controlled study demonstrated that steroids brought about a decrease in pain and an improvement in function as compared with placebo.[35] Furthermore, the study showed no significant differences between higher (40 mg) and lower (20 mg) doses of triamcinolone acetonide. Therefore, in general, lower doses of steroids should be used initially.

Experiences with platelet-rich therapy (PRT) injections of soft tissue injuries (ligament, muscle, and tendon tears; tendinopathies) are increasingly being published. A recent Cochran review cited insufficient evidence to support the use PRT and a need for standardization of platelet-rich plasma preparation.[36]


Antibiotic Therapy

In cases in which septic bursitis is suspected, the bursa should be aspirated. The skin over the bursa is sterilized, and the area is anesthetized with lidocaine via a 27-gauge needle. A 20- or 22-gauge needle is then introduced sterilely into the bursa. Fluid is aspirated and sent for analysis to identify any infectious organisms or crystals present.

Staphylococcus aureus is the most common pathogen in septic bursitis, accounting for more than 80% of cases. Streptococcal species (mostly group A hemolytic streptococci) account for 5-20% of cases. Other gram-positive, gram-negative, and anaerobic infections are rare. Mycobacterial, fungal, algal, and spirochetal infections are even rarer and tend to occur in unusual clinical settings (especially in those who are predisposed to infection).

If bursitis is found to be secondary to infection after aspiration and fluid analysis, treatment should be initiated with antibiotics.[37] An appropriate antistaphylococcal antibiotic should be started empirically. This should be a penicillinase-resistant penicillin, such as oxacillin, or a first-generation cephalosporin, such as cefazolin. In penicillin-allergic patients or in carriers of methicillin-resistant S aureus (MRSA), vancomycin is an appropriate alternative treatment.

In a study involving 82 patients with severe septic bursitis, Martinez-Taboada et al concluded that in patients with severe septic bursitis but without extensive cellulitis, aspiration plus IV cloxacillin may be sufficient treatment, whereas in patients with more severe cases of septic bursitis, aspiration along with cloxacillin plus gentamicin may be appropriate in the majority.[11]

The duration of antibiotic treatment varies with the patient and the clinical situation. Uncomplicated septic bursitis presenting within 7 days of infection should be treated with a minimum 10-day course.[38] Outpatient treatment is effective in 40-50% of patients with mild to moderate infections. A 4-week course is advisable using high doses of sensitivity-directed antibiotics.

Aspiration should be repeated every 1-3 days while antibiotics are being administered. Antibiotics should be continued for 5 days past sterilization of bursal fluid as seen by aspiration. Aspiration also helps to decrease the bacterial load and to promote comfort.

Immunocompromised patients require a longer course of treatment, at least 15 days. Deep bursae infections have higher associations with bacteremia and call for more aggressive and prolonged antibiotic therapy. In particularly severe cases, hospitalization is required, with 1 week of parenteral antibiotics followed by 30 days of oral antibiotics. Surgical drainage or debridement is often necessary.

Treatment of tuberculous bursitis involves full excision of the bursae and surrounding affected tissue with concomitant antituberculous therapy for 6-12 months. Atypical mycobacteria occasionally may be successfully treated with conservative drainage and appropriate antibiotics. Brucella bursitis is treated with excision of bursae and administration of tetracycline with or without rifampin.


Surgical Drainage and Excision

In general, bursitis is not treated surgically. However, there are some cases in which surgical interventions such as the following are appropriate:

  • Incision and drainage
  • Excision of chronically inflamed bursae
  • Removal of underlying bony prominences

As a rule, surgical intervention is reserved for the following situations[39] :

  • Failure of needle aspiration to drain the bursa adequately
  • Bursa site inaccessible to repeated needle aspirations
  • Abscess, necrosis, or sinus formation
  • Need for exploration to assess the extent of infection of adjacent structures
  • Recurrent or refractory disease after conservative treatment

Surgical release may be indicated when adhesive bursitis develops that severely limits joint motion. During surgery, the adhered bursa is removed, and the contiguous tissues are released.[40, 41, 20, 42]

In the upper extremity, subscapular bursitis can be caused by bony exostoses, and surgery may be needed to reduce these structures. In addition, the association of subacromial bursitis with rotator cuff impingement and tears is high, and surgical repair of the tear may be indicated.

In the lower extremity, Baker cysts (popliteal bursitis) are often removed surgically. Before open excision, arthroscopy should be performed to evaluate for intra-articular conditions. Most cysts are approached posteromedially through a hockey-stick incision.

Pretell et al described distal “Z” lengthening of the fascia lata in 13 hips and reported that 12 of the 13 patients reported good results.[43] According to the authors, this technique is less aggressive, can be performed with local anesthesia, and is associated with little morbidity and disability. The mean operating time for the procedure was 15 minutes, and one seroma was reported as a complication.

A small case series from Australia found endoscopic bursectomy to be safe and effective as therapy for infectious prepatellar bursitis and suggested that it reduced the duration of hospitalization and hastened return to work as compared with conventional open surgical treatment.[44]

A systematic review from The Netherlands found that for surgical treatment of chronic retrocalcaneal bursitis, endoscopic approaches appear to yield better results than open approaches; however, more evidence is needed to establish the optimal surgical approach.[20]

Lohrer and Nauck, in a prospective study of 89 athletes who underwent surgery for recalcitrant retrocalcaneal bursitis or recalcitrant midportion Achilles tendinopathy, found that clinical severity scores improved significantly at 6 and 12 months following surgery, and that improvements were similar among patients who did or did not undergo tendon repair.[45]

Contributor Information and Disclosures

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Interim Chief, Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians, American College of Rheumatology

Disclosure: Nothing to disclose.


Janet Kay Talbot-Stern, MD, FACEM, FCEM Emergency Medicine VMO, Ryde and Bankstown Hospitals, Australia Locum Consultant, St Thomas Hospital, UK

Disclosure: Nothing to disclose.

Alita Gonsalves, MD Physiatrist, Private Practice, Vero Orthopaedics and Neurology; Former Staff Physician, Department of Physical Medicine and Rehabilitation, New York Presbyterian Hospital

Alita Gonsalves, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Physiatric Association of Spine, Sports and Occupational Rehabilitation

Disclosure: Nothing to disclose.

Leon Root, MD Professor of Clinical Surgery, Department of Orthopedics, Weill Medical College of Cornell University; Founder and Director, Pediatric Outreach Program; Emeritus Chief of Osteogenesis Imperfecta Clinic, Attending Orthopedic Surgeon, Medical Director of Rehabilitation, Emeritus Chief of Pediatric Orthopedics, The Hospital for Special Surgery

Leon Root, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Association, New York Academy of Medicine, American Academy of Cerebral Palsy and Developmental Medicine, Pediatric Orthopaedic Society of North America

Disclosure: Nothing to disclose.

Chief Editor

Harris Gellman, MD Consulting Surgeon, Broward Hand Center; Voluntary Clinical Professor of Orthopedic Surgery and Plastic Surgery, Departments of Orthopedic Surgery and Surgery, University of Miami, Leonard M Miller School of Medicine, Clinical Professor, Surgery, Nova Southeastern School of Medicine

Harris Gellman, MD is a member of the following medical societies: American Academy of Medical Acupuncture, American Academy of Orthopaedic Surgeons, American Orthopaedic Association, American Society for Surgery of the Hand, Arkansas Medical Society

Disclosure: Nothing to disclose.


Ian D Dickey, MD, FRCSC Adjunct Professor, Department of Chemical and Biological Engineering, University of Maine; Consulting Staff, Adult Reconstruction, Orthopedic Oncology, Department of Orthopedics, Eastern Maine Medical Center

Ian D Dickey, MD, FRCSC is a member of the following medical societies: American Academy of Orthopaedic Surgeons, British Columbia Medical Association, Canadian Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Stryker Orthopaedics Consulting fee Consulting; Cadence Honoraria Speaking and teaching

Gino A Farina, MD, FACEP, FAAEM Associate Professor of Clinical Emergency Medicine, Albert Einstein College of Medicine; Program Director, Department of Emergency Medicine, Long Island Jewish Medical Center

Gino A Farina, MD, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mark Louden, MD Assistant Professor of Clinical Medicine, Division of Emergency Medicine, Department of Medicine, University of Miami, Leonard M Miller School of Medicine

Mark Louden, MD is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians

Disclosure: Nothing to disclose.

Heidi M Stephens, MD, MBA Associate Professor, Department of Surgery, Division of Orthopedic Surgery, University of South Florida College of Medicine; Courtesy Joint Associate Professor, Department of Environmental and Occupational Health, University of South Florida College of Public Health

Heidi M Stephens, MD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, American Medical Association, American Orthopaedic Foot and Ankle Society, and Florida Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Crenshaw AH, Canale ST. Nontraumatic disorders. Canale ST, ed. Campbell’s Operative Orthopaedics. 9th ed. St Louis: Mosby; 1998. 776-85.

  2. DeLee JC, Drez D. Imaging effusions, cysts, and ganglia. DeLee JC, Drez D, Miller MD, eds. DeLee and Drez’s Orthopaedic Sports Medicine: Principles and Practice. Philadelphia: WB Saunders; 2003. 1646-8.

  3. Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention. 3rd ed. Baltimore: Williams and Wilkins; 1996.

  4. Salzman KL, Lillegard WA, Butcher JD. Upper extremity bursitis. Am Fam Physician. 1997 Nov 1. 56(7):1797-806, 1811-2. [Medline].

  5. Butcher JD, Salzman KL, Lillegard WA. Lower extremity bursitis. Am Fam Physician. 1996 May 15. 53(7):2317-24. [Medline].

  6. Keplinger FS, Gupta N. :. Knee bursitis. Frontera WR, Silver JK, eds. Essentials of Physical Medicine and Rehabilitation. 340-4. Philadelphia: Hanley & Belfus; 2002.

  7. McAfee JH, Smith DL. Olecranon and prepatellar bursitis. Diagnosis and treatment. West J Med. 1988 Nov. 149(5):607-10. [Medline]. [Full Text].

  8. Hirji Z, Hunjun JS, Choudur HN. Imaging of the bursae. J Clin Imaging Sci. 2011. 1:22. [Medline]. [Full Text].

  9. Reilly JP, Nicholas JA. The chronically inflamed bursa. Clin Sports Med. 1987 Apr. 6(2):345-70. [Medline].

  10. Chen MJ, Lew HL, Hsu TC, Tsai WC, Lin WC, Tang SF, et al. Ultrasound-guided shoulder injections in the treatment of subacromial bursitis. Am J Phys Med Rehabil. 2006 Jan. 85(1):31-5. [Medline].

  11. Blankstein A, Ganel A, Givon U, Mirovski Y, Chechick A. Ultrasonographic findings in patients with olecranon bursitis. Ultraschall Med. 2006 Dec. 27(6):568-71. [Medline].

  12. Turan H, Serefhanoglu K, Karadeli E, Timurkaynak F, Arslan H. A case of brucellosis with abscess of the iliacus muscle, olecranon bursitis, and sacroiliitis. Int J Infect Dis. 2009 Nov. 13(6):e485-7. [Medline].

  13. Malkin J, Shrimpton A, Wiselka M, Barer MR, Duddridge M, Perera N. Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease. J Med Microbiol. 2009 Mar. 58:371-3. [Medline].

  14. Brinks A, van Rijn RM, Bohnen AM, Slee GL, Verhaar JA, Koes BW, et al. Effect of corticosteroid injection for trochanter pain syndrome: design of a randomised clinical trial in general practice. BMC Musculoskelet Disord. 2007 Sep 19. 8:95. [Medline]. [Full Text].

  15. Alvarez-Nemegyei J, Canoso JJ. Evidence-based soft tissue rheumatology: III: trochanteric bursitis. J Clin Rheumatol. 2004 Jun. 10(3):123-4. [Medline].

  16. Rowand M, Chambliss ML, Mackler L. Clinical inquiries. How should you treat trochanteric bursitis?. J Fam Pract. 2009 Sep. 58(9):494-500. [Medline].

  17. Viradia NK, Berger AA, Dahners LE. Relationship between width of greater trochanters and width of iliac wings in tronchanteric bursitis. Am J Orthop (Belle Mead NJ). 2011 Sep. 40(9):E159-62. [Medline].

  18. Alvarez-Nemegyei J. Risk factors for pes anserinus tendinitis/bursitis syndrome: a case control study. J Clin Rheumatol. 2007 Apr. 13(2):63-5. [Medline].

  19. Alvarez-Nemegyei J, Canoso JJ. Evidence-Based Soft Tissue Rheumatology IV: Anserine Bursitis. J Clin Rheumatol. 2004 Aug. 10(4):205-6. [Medline].

  20. Wiegerinck JI, Kok AC, van Dijk CN. Surgical treatment of chronic retrocalcaneal bursitis. Arthroscopy. 2012 Feb. 28(2):283-93. [Medline].

  21. Torralba KD, Quismorio FP Jr. Soft tissue infections. Rheum Dis Clin North Am. 2009 Feb. 35(1):45-62. [Medline].

  22. Le Manac'h AP, Ha C, Descatha A, Imbernon E, Roquelaure Y. Prevalence of knee bursitis in the workforce. Occup Med (Lond). 2012 Jul 9. [Medline].

  23. Guanche CA. Clinical update: MR imaging of the hip. Sports Med Arthrosc. 2009 Mar. 17(1):49-55. [Medline].

  24. D'Agostino MA, Schmidt WA. Ultrasound-guided injections in rheumatology: actual knowledge on efficacy and procedures. Best Pract Res Clin Rheumatol. 2013 Apr. 27(2):283-94. [Medline].

  25. Tsai YH, Huang TJ, Hsu WH, Huang KC, Li YY, Peng KT, et al. Detection of subacromial bursa thickening by sonography in shoulder impingement syndrome. Chang Gung Med J. 2007 Mar-Apr. 30(2):135-41. [Medline].

  26. Zuinen C. Diclofenac/misoprostol vs diclofenac/placebo in treating acute episodes of tendinitis/bursitis of the shoulder. Drugs. 1993. 45 Suppl 1:17-23. [Medline].

  27. Wittich CM, Ficalora RD, Mason TG, Beckman TJ. Musculoskeletal injection. Mayo Clin Proc. 2009 Sep. 84(9):831-6; quiz 837. [Medline]. [Full Text].

  28. Jacobs JW. How to perform local soft-tissue glucocorticoid injections. Best Pract Res Clin Rheumatol. 2009 Apr. 23(2):193-219. [Medline].

  29. Buchbinder R, Green S, Youd JM, Johnston RV. Oral steroids for adhesive capsulitis. Cochrane Database Syst Rev. 2006 Oct 18. CD006189. [Medline].

  30. Smith DL, McAfee JH, Lucas LM, Kumar KL, Romney DM. Treatment of nonseptic olecranon bursitis. A controlled, blinded prospective trial. Arch Intern Med. 1989 Nov. 149(11):2527-30. [Medline].

  31. Sayegh ET, Strauch RJ. Treatment of olecranon bursitis: a systematic review. Arch Orthop Trauma Surg. 2014 Nov. 134 (11):1517-36. [Medline].

  32. Shbeeb MI, O'Duffy JD, Michet CJ Jr, O'Fallon WM, Matteson EL. Evaluation of glucocorticosteroid injection for the treatment of trochanteric bursitis. J Rheumatol. 1996 Dec. 23(12):2104-6. [Medline].

  33. Costantino TG, Roemer B, Leber EH. Septic arthritis and bursitis: emergency ultrasound can facilitate diagnosis. J Emerg Med. 2007 Apr. 32(3):295-7. [Medline].

  34. Farmer KW, Jones LC, Brownson KE, Khanuja HS, Hungerford MW. Trochanteric bursitis after total hip arthroplasty: incidence and evaluation of response to treatment. J Arthroplasty. 2010 Feb. 25(2):208-12. [Medline].

  35. Hong JY, Yoon SH, Moon do J, Kwack KS, Joen B, Lee HY. Comparison of high- and low-dose corticosteroid in subacromial injection for periarticular shoulder disorder: a randomized, triple-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2011 Dec. 92(12):1951-60. [Medline].

  36. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2013 Dec 23. 12:CD010071. [Medline].

  37. Martinez-Taboada VM, Cabeza R, Cacho PM, Blanco R, Rodriguez-Valverde V. Cloxacillin-based therapy in severe septic bursitis: retrospective study of 82 cases. Joint Bone Spine. 2009 Dec. 76(6):665-9. [Medline].

  38. Zimmermann B 3rd, Mikolich DJ, Ho G Jr. Septic bursitis. Semin Arthritis Rheum. 1995 Jun. 24(6):391-410. [Medline].

  39. Slawski DP, Howard RF. Surgical management of refractory trochanteric bursitis. Am J Sports Med. 1997 Jan-Feb. 25(1):86-9. [Medline].

  40. Baker CL Jr, Massie RV, Hurt WG, Savory CG. Arthroscopic bursectomy for recalcitrant trochanteric bursitis. Arthroscopy. 2007 Aug. 23(8):827-32. [Medline].

  41. Baums MH, Spahn G, Nozaki M, Steckel H, Schultz W, Klinger HM. Functional outcome and general health status in patients after arthroscopic release in adhesive capsulitis. Knee Surg Sports Traumatol Arthrosc. 2007 May. 15(5):638-44. [Medline].

  42. Le Lievre HM, Murrell GA. Long-term outcomes after arthroscopic capsular release for idiopathic adhesive capsulitis. J Bone Joint Surg Am. 2012 Jul 3. 94(13):1208-16. [Medline].

  43. Pretell J, Ortega J, García-Rayo R, Resines C. Distal fascia lata lengthening: an alternative surgical technique for recalcitrant trochanteric bursitis. Int Orthop. 2009 Oct. 33(5):1223-7. [Medline]. [Full Text].

  44. Dillon JP, Freedman I, Tan JS, Mitchell D, English S. Endoscopic bursectomy for the treatment of septic pre-patellar bursitis: a case series. Arch Orthop Trauma Surg. 2012 Jul. 132(7):921-5. [Medline].

  45. Lohrer H, Nauck T. Results of operative treatment for recalcitrant retrocalcaneal bursitis and midportion Achilles tendinopathy in athletes. Arch Orthop Trauma Surg. 2014 Aug. 134 (8):1073-81. [Medline].

  46. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD007400. [Medline].

Olecranon bursitis, shown here with elbow flexed. Image courtesy of UMDNJ-New Jersey Medical School,, and
Olecranon bursitis: aspiration of hemorrhagic effusion. Image courtesy of UMDNJ-New Jersey Medical School,, and
Location of anserine (pes anserinus) bursa on medial knee. MCL=medial collateral ligament.
Acute infectious bursitis upon presentation to emergency department. Image courtesy of Christopher Kabrhel, MD.
Infectious bursitis. Image courtesy of Christopher Kabrhel, MD.
Shoulder anatomy muscle, anterior view.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.